Business Wire

MI-EATON

8.9.2022 12:31:47 CEST | Business Wire | Press release

Share
Eaton to showcase innovative electrified commercial vehicle technologies at IAA Transportation show

Power management company Eaton will display technologies to support the zero emissions journey in the commercial vehicle market Sept. 20-25 at the IAA Transportation show in Hannover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005014/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s eMobility business provides electrified vehicle solutions for its global commercial vehicle customers. (Photo: Business Wire)

“We are helping our customers around the globe with technologies that solve some of the toughest challenges throughout the electrified vehicle (EV) ecosystem,” said Scott Adams, president, Eaton’s eMobility business. “Eaton provides a vast portfolio of EV technologies for full battery electric, fuel cell and hybrid commercial vehicles, as well as EV charging infrastructure solutions.”

Flex Power Distribution Unit delivers safe power for commercial electrified vehicles

Eaton’s eMobility business offers a new Flex Power Distribution Unit (PDU) for high-voltage electrified commercial vehicles that is uniquely designed to handle multiple load requirements.

The Flex PDU integrates Eaton’s Breaktor® circuit protection technology, which improves vehicle safety and protects components from any level of overcurrent condition more effectively than traditional circuit protection methods. The Breaktor circuit protection solution is resettable like a circuit breaker, enabling reactivation of the device following a functionality check and reducing cost for both the OEM and consumer.

The Flex PDU also leverages sealed and corrosion-resistant terminals and connectors from Royal Power Solutions, a global leader in power distribution and transmission solutions that Eaton acquired earlier this year. Eaton’s Bussmann® series fuses are also integrated to meet the requirements for use in the latest high-powered electrified vehicles with ratings up to 1,000 volts of direct current (VDC) and 600 amps.

Eaton’s Flex PDU protects vital components and occupants and is also an intelligent unit that provides the OEM diagnostic information, including where the most power is being consumed, to maximize performance and efficiency. Its integrated and optimized design reduces the number of components, lessening complexity.

Electrified vehicle transmissions, gearing improves performance, range

Eaton’s new 4-speed transmissions provide superior performance on grades and acceleration for electrified commercial vehicles while offering more flexible gear ratios compared to competitive technologies. The compact 4-speed transmissions for medium- and heavy-duty electrified commercial vehicles also improve system efficiency, enabling longer vehicle range and battery life.

“We supply transmissions for multiple global commercial vehicle manufacturers, and many more are interested,” Adams said. “With decades of experience, we continue to build on our heritage as a top supplier of commercial vehicle transmissions.”

DC-DC converters available in a range of power configurations

Eaton recently introduced a 48-volt DC-DC converter to power accessories such as antilock brakes and lighting for commercial vehicles with 48-volt electrical systems. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.

Eaton’s DC-DC converter portfolio covers a spectrum of power requirements, ranging from low- to high-voltage systems, depending on customer specifications. The converters can be tuned for particular duty cycles via their advanced digital control architecture, enabling flexible control modes through firmware adaptation.

Green Motion acquisition bolsters Eaton’s vehicle charging capabilities

In March 2021, Eaton acquired Switzerland-based Green Motion SA, a leading designer and manufacturer of electric vehicle charging hardware and related software. Eaton’s efficient electric vehicle charging infrastructure expertise includes the production and operation of charging stations, designing management software for charging networks, and serving as an electric mobility service provider.

‘Buildings as a Grid’ strategy expands charging possibilities

Many workplaces host vehicle fleets, such as cars for the salesforce and vans for deliveries. Fleet managers switching to EVs, either now or in the future, will want to electrify their fleet while ensuring business continuity. Eaton’s “Buildings as a Grid” approach helps fleet managers devise an EV charging strategy that is fast to implement, cybersecure and scalable so that they can add more EV charging capacity when needed.

The strategy may include EV charging infrastructure at their site or depot, on-site renewables like solar panels on buildings, and options for fleet drivers to charge at home and when they are traveling. Eaton’s digital and physical infrastructure transforms a workplace or depot into an energy hub, and because it is a gateway to electrifying the entire functionality of the site, it is also an investment in the energy transition.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, operate sustainably, and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for its stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005014/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye